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ABSTRACT: APOBEC3B (A3B) deamination activity on
ssDNA is considered a contributing factor to tumor
heterogeneity and drug resistance in a number of human
cancers. Despite its clinical impact, little is known about A3B
ssDNA substrate preference. We have used nuclear magnetic
resonance to monitor the catalytic turnover of A3B substrates in
real-time. This study reports preferred nucleotide sequences for
A3B substrates, including optimized 4-mer oligonucleotides, and
reveals a breadth of substrate recognition that includes DNA
sequences known to be mutated in drug-resistant cancer clones.
Our results are consistent with available clinical and structural
data and may inform the design of substrate-based A3B
inhibitors.
The human APOBEC3 (apolipoprotein B mRNA editingenzyme, catalytic polypeptide-like) cytidine deaminase
family comprises seven members, which convert C to U on
single stranded DNA (ssDNA), among other functions.1,2
APOBEC proteins contain either one (A3A/A3C/A3H) or
two domains (A3B/A3DE/A3F/A3G) with similar overall
architecture. Although each domain incorporates a zinc
binding site, in the case of A3B only the C-terminal domain
(CTD) has been associated with catalytic activity.3,4 Activity-
modulating functions of the N-terminal domain (NTD) have
been proposed;2 however, expression and puriﬁcation of full-
length recombinant wild-type A3B has proven challenging.4 As
part of the innate immune system, APOBEC proteins are
upregulated in response to viral infection, for example, human
immunodeﬁciency virus type 1 or human papilloma virus,
where they deaminate viral genomes and restrict viral
replication.1,5 However, several members have also been
linked to cancer, and A3B in particular has been associated
with increased mutational burden in head and neck, cervical,
lung, bladder, and breast cancer.6 Depending on subsequent
repair mechanisms, APOBEC-mediated deamination pre-
dominantly causes C→T transition and C→G transversion,7
thereby contributing to mutational load, tumor heterogeneity,
and the development of drug resistance.8 A3B inhibition with
small molecules is therefore considered a promising
therapeutic strategy to combat drug resistance in cancer
patients. Several studies have analyzed the sequence context of
APOBEC-mediated deamination in vitro and from patient
sequencing data, identifying a consensus sequence of 5′-TC-3′
(the target C is henceforth underlined) for A3A, A3B, A3F,
and A3H, while A3G prefers a 5′-CCC-3′ consensus
sequence.2,9−19 A recent study has further evaluated the eﬀect
of oligonucleotide length and substrate context on the A3B
CTD deamination rate.20 However, a systematic study of A3B
substrate sequence preference has not been reported. We use
real-time nuclear magnetic resonance (NMR) experiments to
determine the impact of substrate sequence and length on
turnover rate by wild-type A3B CTD. Through these studies,
we further inform the biological and clinical relevance of A3B
activity and gain insight into its molecular mechanism.
We found that the 10-mer APOBEC3B substrate sequence
5′-TTATTCATAT-3′ contained in the 30 nucleotide (nt)
FAM-labeled ssDNA substrate reported by Fu et al.3 was
readily deaminated by A3B CTD in a ﬂuorescence-based
deamination assay (Figure S1) and by NMR (Figure 1A, Table
S1) with an initial rate of 0.174 ± 0.042 mM·h−1 (n = 3, ±SD).
By contrast, no deamination of the mononucleotide 2′-
deoxycytidine 5′-monophosphate (5′-dC-3′, dCMP) or the
commonly reported A3B preferred motif 5′-TCA-3′10,13 was
observed after a 5 h incubation (Figure 1A, Table S1). When
we extended the incubation time to 20 h, we detected 20%
conversion for 5′-TCA-3′, a deamination rate of 0.007 ± 0.001
mM·h−1 (n = 3, ±SD), 25-fold slower than for the 10-mer 5′-
TTATTCATAT-3′. We did not observe any deamination for
dCMP even after 50 h incubation.
Using the 10-mer oligonucleotide 5′-TTATTCATAT-3′ as a
benchmark, we set out to determine the contribution to A3B
CTD-mediated deamination of nucleotides both (−) (i.e., 5′)
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and (+) (i.e., 3′) to C. Dinucleotides, such as 5′-TC-3′ and 5′-
CA-3′, were not deaminated by A3B CTD. When we added a
second nucleotide on the (+) side, we observed deamination of
the trimer 5′-CAT-3′ with an initial rate of 0.023 ± 0.001 mM·
h−1 (n = 3, ±SD) (Figure 1B, Figure S2, and Table S1), 8-fold
slower than the 10-mer. Notably, 5′-CAT-3′ is the smallest
oligonucleotide for which we observed deamination after a 5 h
incubation. Shi et al. suggested that aromatic π-stacking of
nucleobases positioned +1 to +3 to the substrate C contribute
to productive deamination.13 However, in our hands, further
extension of the 5′-CAT-3′ oligonucleotide to tetra- and
pentanucleotides using a poly-T sequence had little eﬀect
(Figure 1B, Figure S2, and Table S1), indicating that
nucleotides at positions +3 and +4 do not further enhance
substrate turnover rate. A similar study on the (−) side of the
substrate C showed lower deamination rate compared with
their matched (+) side equivalents (Figure 1B, Figure S2, and
Table S1). For example, no deamination was observed for 5′-
TTC-3′ after 5 h incubation and a deamination rate could only
be obtained with extended incubation time (15 h) [0.009 ±
0.002 mM·h−1 (n = 4, ±SD) (Figure 1B, Figure S2, and Table
S1)]. The initial deamination rates of oligonucleotides
extended in either the (−) or the (+) direction are depicted
as bar charts in Figure S2, and deamination rates are provided
in Table S1.
These results prompted us to further investigate the +1
nucleotide. Intriguingly, introduction of A to the +1 position of
5′-TTC-3′ increased the deamination rate to a level similar to
the 10-mer rate [5′-TTCA-3′ initial rate = 0.107 ± 0.014 mM·
h−1 (n = 3, ±SD)]. This eﬀect was also observed for 5′-ATTC-
3′; addition of a +1 A (5′-ATTCA-3′) fully restored the
deamination rate to that of the 10-mer (Figure 1C, left, and
Table S1). These observations suggest that the +1 nucleotide is
important for productive substrate turnover. Analogously, we
added T to the −1 position of oligonucleotide 5′-CAT-3′. The
resultant 5′-TCAT-3′ sequence showed low catalytic turnover,
which could be improved by addition of a second nucleotide
on the (−)-side (Figure 1C, right, and Table S1). Thus, only
one nucleotide at the (−)-side appears detrimental, whereas
addition of both −1 and −2 nucleotides enhances the
deamination rate ∼6-fold compared to the 5′-CAT-3′
trinucleotide. Crystal structures of A3A and a chimeric A3A/
A3B CTD crystal structure in complex with ssDNA substrates
reveal large conformational changes of Tyr132 (A3A), Tyr315
(A3B), and Arg211 (A3B)13 in relation to the apo
structures16,21 in order to accommodate T at the −1 position.
Our results suggest that the speciﬁc interactions of −1 T with
Asp314 are not suﬃcient to stabilize a productive protein
conformation, and further interactions of the −2 nucleotide
with the protein may be required. This could explain why
deamination, albeit weakly, of (+)-side only nucleotides was
observed; the turnover of such substrates may not require such
conformational adaptation of A3B.
As the shortest oligonucleotide substrate subject to notable
deamination was the tetramer 5′-TTCA-3′, we investigated
whether the directionality of ssDNA presentation is important
Figure 1. Impact of (+) and (−) side nucleotides on substrate turnover. (A) Representative 1H NMR spectra recorded over a time course are
shown for the 10-mer 5′-TTATTCATAT-3′, dCMP and 5′-TCA-3′. The intensities of the C peak were used to monitor substrate turnover and to
calculate the initial reaction rates. (B) Time course of deamination rates for 10-mer 5′-TTATTCATAT-3′, dCMP, and (+) and (−) side only
oligonucleotides. (C) Addition of +1A (left) and two T nucleotides at the (−) side (right) increase turnover of the substrate oligo, whereas a single
T on the (−) side appears detrimental. ns not signiﬁcant, *p-value < 0.05, ***p-value < 0.001, One-way ANOVA and Bonferroni test.
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for short oligonucleotides. We tested the corresponding 5′-
ACTT-3′ sequence (equivalent to 3′-TTCA-5′) and observed
no deamination (Figure 2A and Table S1). Using a crystal
structure of 5′-TTCA-3′ in complex with the A3A/A3B CTD
chimera,13 we modeled 3′-dC-5′ into the catalytic site to
understand the diﬀerence between 5′-dC-3′ and 3′-dC-5′
binding at an atomic level. Constraining the cytidine base
within the catalytic site to a productive binding mode and
altering the ssDNA directionality from 5′-dC-3′ to 3′-dC-5′
revealed severe clashes with the protein surface (Figure 2B)
due to the ﬁxed chirality of the ribose sugar (Figure 2C).
Work by Byeon et al.9 suggested that A at the −2 position,
that is, 5′-ATCA-3′, is a better A3B substrate than 5′-TTCA-
3′, and consistent with their report, we determined an initial
rate of 0.205 ± 0.041 mM·h−1 (n = 3, ±SD) for 5′-ATCA-3′
compared to 0.107 ± 0.014 mM·h−1 (n = 3, ±SD) for 5′-
TTCA-3′ (p-value = 0.0166, unpaired t test). This observation
raised further questions concerning A3B substrate preference,
and we therefore systematically evaluated the impact of all
possible nucleobases at positions −2, −1, and +1 using the 5′-
ATCA-3′ sequence as a benchmark.
Consistent with previous reports,9 only −1 T was
compatible with substrate turnover in a 4-mer oligonucleotide
substrate. Deamination was reduced with −1 C and absent
with −1 A and −1 G (Figure 3A and Table S1); probably due
to extensive interactions of −1 T with A3B13 and potential
steric restrictions associated with the binding of larger purine
bases.22
Figure 2. Inﬂuence of ssDNA directionality on substrate turnover. (A) The 5′ → 3′ sequence TTCA but not the corresponding 3′ → 5′ TTCA
(equivalent to 5′-ACTT-3′) oligonucleotide is deaminated by A3B CTD. (B) Binding of 3′→ 5′ deoxycytidine monophosphate (dCMP, orange),
but not 5′→ 3′ dCMP (green) results in severe clashes with the A3B protein (blue cartoon/spheres and gray surface). Therefore, only the 5′→ 3′
dCMP is compatible with binding; the crystal structure conformation of the base is ﬁxed in a productive binding mode; PDB entry 5TD5 was
used.13 (C) Due to the chirality of the deoxyribose sugar, the 3′ and 5′ ends adopt diﬀerent vectors in 5′ → 3′ and 3′ → 5′ dCMP; the cytosine
base is depicted in the same orientation, which is required for productive deamination (Figure 2B).
Figure 3. A3B CTD base preference at diﬀerent substrate positions translates to biologically relevant DNA sequences. (A) Based on the 5′-ATCA-
3′ sequence as a benchmark, the eﬀect of diﬀerent bases at positions −2, −1, and +1 on substrate turnover was evaluated. Preference for G at +1 is
also observed with the (+)-side trimer oligonucleotides (p-value = 0.0046, unpaired t test). (B) Oligonucleotides representing commonly observed
drug resistance mutations containing identiﬁed substrate sequences 5′-TTCA-3′ (PIK3CA E452), 5′-ATCA-3′ (Kit D820), 5′-GTCG-3′ (Smo
D473), and 5′-ATCG-3′ (Kit D716) are deaminated at a similar or higher rate to the 10-mer positive control 5′-TTATTCATAT-3′, whereas no
turnover was observed for the negative control 5′-TACA-3′ (Kit T670) after 20 h. Notably, all drug resistance mutations except Kit T670I aﬀect
the complementary strand. The 10-mer and 5′-CAT-3′ deamination rates from previous experiments are plotted as a reference. ns not signiﬁcant,
*p-value < 0.05, **p-value < 0.01, ***p-value < 0.001, One-way ANOVA and Bonferroni test.
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Variation of the −2 nucleobase also inﬂuenced substrate
turnover, with −2 G representing the best deamination
substrate (Figure 3A and Table S1).
Variations at the +1 position of 4-mer substrates had less
impact compared to the −1 position with 5′-ATCG-3′ the best
substrate (Figure 3A and Table S1). Preference for +1 G was
also observed in the (+)-side only trinucleotides, with initial
rates of 0.023 ± 0.001 (n = 3, ± SD) vs 0.093 ± 0.021 (n = 3,
± SD) mM·h−1 for 5′-CAT-3′ and 5′-CGT-3′ (Figure 3A and
Table S1). Combining these position-dependent results
suggested 5′-GTCG-3′ as an optimal A3B substrate; this
oligonucleotide was deaminated at a similar rate to 5′-ATCG-
3′ and 5′-GTCA-3′. Intriguingly, these 4-mer substrates were
deaminated at a similar rate compared to the control 10-mer
oligonucleotide 5′-TTATTCATAT-3′ (p-value > 0.05 for 5′-
ATCG-3′, 5′-GTCA-3′, and 5′-GTCG-3′, One-way ANOVA
and Bonferroni test). Other studies have suggested that longer
ssDNA oligo substrates are required for binding22 and
deamination by the closely related A3A enzyme;17 however,
our data demonstrates proﬁcient A3B substrate turnover with
short oligos provided the sequence context is appropriate.
To further investigate the biological relevance of our
ﬁndings, we tested commonly observed mutations in cancer
patients, where mutation of a C base is consistent with the
generation of clones known to confer resistance to cancer
therapy (Figure 3B and Table S1). For example, mutations
within the Kit and Smoothened (Smo) genes confer resistance
to targeted cancer drugs such as imatinib (Kit D820Y and
D716N) and vismodegib (Smo D473H/N/Y).23 These
clinically identiﬁed mutations may all result from A3B-
mediated lesions, which can be further processed by DNA
repair mechanisms to give the observed amino acid change.
Oligonucleotides (10-mers) containing mutation sites within
the identiﬁed substrate sequences 5′-ATCA-3′ (Kit D820Y),
5′-ATCG-3′ (Kit D716N), and 5′-GTCG-3′ (Smo D473H/
N/Y) were rapidly deaminated at a similar rate to the 5′-
TTATTCATAT-3′ 10-mer substrate. Furthermore, the
oligonucleotide representing the PIK3CA E542K mutation
previously associated with A3B-activity24 was also deaminated.
In contrast, no deamination of 5′-TACA-3′ (Kit T670I), which
is not a predicted A3B substrate, was observed after 20 h.
These ﬁndings provide a mechanistic rationale for A3B-
mediated generation of mutations that sustain the emergence
of resistant clones under the selective pressure of targeted
cancer therapy.
Deamination of 5′-GTCG-3′ and 5′-ATCG-3′-containing
substrates at rates comparable to the 5′-TTATTCATAT-3′ 10-
mer suggests that their productive deamination is determined
by both speciﬁc interactions of −1, −2, and +1 substrate
nucleotides, as well as the modiﬁed C, with A3B-CTD.
Furthermore, the secondary structure and conformation of the
substrate may be important, consistent with the reported
increased A3B binding of hairpin versus linear oligonucleo-
tides.25
Previous A3B CTD NMR deamination studies of +1 base
variations in the context of 40-mers are consistent with our
results,9 thereby suggesting that the preference for bases
immediately adjacent to the substrate C is conserved and
independent from the composition or length of the overall
oligonucleotide. This suggests that interactions with residues
close to, but not within, the catalytic site are required for tight
and speciﬁc binding of ssDNA, or for optimal positioning of
the substrate C for productive deamination, or both. As
discussed above, structural data on A3B ssDNA binding is fully
consistent with the preference for T at position −1 and gives
insights into possible induced-ﬁt mechanisms for substrate
binding. However, structural data to inform on potential
interactions of −2 and +1 nucleotides is lacking because the
reported A3B−ssDNA crystal structure includes alterations to
A3B loop regions 1 and 3.13 Due to their proximity to the
substrate-binding site, these loops are likely to be critical to
binding of the −2 and +1 nucleobases (Figure S3).
Conﬂicting evidence is available regarding the substrate
speciﬁcity of the full-length A3B protein compared to CTD
alone: A study by Hache ́ et al. showed that APOBEC substrate
speciﬁcity is not aﬀected by the NTD sequence and is
determined by the CTD alone.26 By contrast, Byeon et al.
reported a similar extent of deamination by full-length A3B in
cell extracts at 5 h for 40-mer substrates with varying
nucleobases at the +1 position; however, initial deamination
rates were not reported.9 More detailed analyses of the impact
of full-length protein on deamination rate and substrate
speciﬁcity are required and will be the subject of future work.
Our studies investigate the impact of substrate length and
composition on deamination rate by A3B. Direct comparison
with other A3 isoforms is limited by the available data;
however, a preference of A3A for a pyrimidine at position −2
has been reported.9,22 In contrast, we observe that A3B-
mediated deamination is enhanced with purine bases at the −2
position consistent with the ﬁndings of Byeon et al.9 These
results indicate a potential for A3A and A3B substrate
speciﬁcity [XTCY (A3A)22 and YTCZ (A3B; this study),
where X is a pyrimidine base, Y is a purine base, and Z can be
any base (although T may be suboptimal)]. Importantly, this is
consistent with diﬀerences observed in cancer patient samples,
where A3A and A3B associated mutations can be distinguished
based on the identity of the −2 base.11 Furthermore, the
mutational pattern observed in patient samples with A3B gene
deletion but A3A gene retention is consistent with an A3A-
substrate preference.11 In the cellular environment, ssDNA is
coated with replication protein A (RPA); however, a recent
study showed that full-length A3B can compete with RPA
binding to ssDNA.27 Together, these studies suggest that our
ﬁndings are biologically and clinically relevant. Similar studies
on related isoforms such as A3F and A3H would be highly
desirable to dissect the contribution of each APOBEC family
member to the mutational load observed in distinct disease
states.
In summary, our studies reveal a broader A3B substrate
sequence recognition than previously reported, which may
widen the clinical context of A3B-mediated mutational
signatures. TCG sequences are removed from bioinformatic
characterization so that the events are not confused with CpG
islands, where methylated C can be deaminated directly to T in
a non-APOBEC-driven manner.24 However, our results suggest
that G is equal or even preferred to A and the contribution of
A3B to mutagenesis in the genome may therefore be
underestimated. We observe equivalent deamination rates for
optimized short tetranucleotide sequences compared to 10-
mer nucleotides suggesting that induced-ﬁt recognition of A3B
CTD for its substrates can be triggered by an optimal
tetranucleotide binding motif, which may facilitate the rational
design of substrate-based A3B-selective inhibitors. The
substrate preference identiﬁed in this study also translates to
biologically relevant DNA sequences. We demonstrate that
A3B CTD deaminates oligonucleotides derived from sequen-
ACS Chemical Biology Letters
DOI: 10.1021/acschembio.8b00639
ACS Chem. Biol. XXXX, XXX, XXX−XXX
D
ces associated with clinical resistance to cancer therapy,
thereby supporting previous evidence that A3B activity
contributes to the evolution of resistance in cancer.
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